NASDAQ:XBIT XBiotech (XBIT) Stock Forecast, Price & News $4.36 -0.20 (-4.39%) (As of 09/22/2023 ET) Add Compare Share Share Today's Range$4.36▼$4.5650-Day Range$4.36▼$5.8152-Week Range$3.00▼$6.69Volume7,375 shsAverage Volume21,352 shsMarket Capitalization$132.72 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media About XBiotech (NASDAQ:XBIT) StockXBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.Read More XBIT Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart XBIT Stock News HeadlinesAugust 8, 2023 | finanznachrichten.deXBiotech Inc.: XBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis (RA) Clinical TrialAugust 8, 2023 | finance.yahoo.comXBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis (RA) Clinical TrialSeptember 24, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...June 30, 2023 | thestreet.comXBiotech Cancer Drug Survival Claim Falls Apart Under ScrutinyMay 23, 2023 | finanznachrichten.deXBiotech Inc.: FDA Authorizes Phase II Study for Natrunix in Rheumatoid Arthritis PatientsMay 22, 2023 | finance.yahoo.comFDA Authorizes Phase II Study for Natrunix in Rheumatoid Arthritis PatientsMay 17, 2023 | finanznachrichten.deXBiotech Inc.: XBiotech Commences Tender Offer to Purchase up to $80,000,000 Worth of Its SharesMay 17, 2023 | finance.yahoo.comXBiotech Commences Tender Offer to Purchase up to $80,000,000 Worth of Its SharesSeptember 24, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...April 17, 2023 | finanznachrichten.deXBiotech Inc.: XBiotech Announces First Subject Enrollment in Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for StrokeApril 17, 2023 | finance.yahoo.comXBiotech Announces First Subject Enrollment in Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for StrokeApril 9, 2023 | finance.yahoo.comXBiotech Inc.'s (NASDAQ:XBIT) top owners are individual investors with 51% stake, while 36% is held by insidersFebruary 15, 2023 | finance.yahoo.comThe past three years for XBiotech (NASDAQ:XBIT) investors has not been profitableNovember 11, 2022 | finance.yahoo.comXBiotech Third Quarter 2022 Earnings: US$0.42 loss per share (vs US$0.11 loss in 3Q 2021)October 31, 2022 | finance.yahoo.comInsiders own 35% of XBiotech Inc. (NASDAQ:XBIT) shares but individual investors control 47% of the companyOctober 18, 2022 | prnewswire.comHelicobacter pylori Infection Market to Exhibit Growth at a Paltry CAGR of 1.9% During the Forecast Period (2022-2032) | DelveInsight - PR NewswireOctober 13, 2022 | finance.yahoo.comXBiotech Announces First Patient Enrolled into the French National Cancer Institute (INCA) Sponsored Phase I/II/III Clinical Study for Natrunix™ Therapy for Colorectal Cancer - Yahoo FinanceOctober 13, 2022 | globenewswire.comXBiotech Announces First Patient Enrolled into the French National Cancer Institute (INCA) Sponsored Phase I/II/III Clinical Study for Natrunix™ Therapy for Colorectal Cancer - GlobeNewswireOctober 13, 2022 | finance.yahoo.comXBiotech Announces First Patient Enrolled into the French National Cancer Institute (INCA) Sponsored Phase I/II/III Clinical Study for Natrunix™ Therapy for Colorectal CancerSeptember 8, 2022 | finance.yahoo.comXBiotech (NASDAQ:XBIT) shareholders have endured a 73% loss from investing in the stock a year agoSeptember 2, 2022 | nasdaq.comWe Think XBiotech (NASDAQ:XBIT) Can Afford To Drive Business Growth - NasdaqAugust 14, 2022 | finance.yahoo.comWe Think XBiotech (NASDAQ:XBIT) Can Afford To Drive Business Growth - Yahoo FinanceAugust 10, 2022 | marketscreener.comXBIOTECH INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q) | MarketScreener - Marketscreener.comJuly 29, 2022 | marketscreener.comJOHNSON & JOHNSON MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q) - Marketscreener.comJune 21, 2022 | benzinga.comThe Daily Biotech Pulse: Thumbs Down For Acadia's Pimavanserin, Pfizer Buys Stake In Valneva, AstraZeneca - BenzingaJune 20, 2022 | globenewswire.comXBiotech Announces Successful Completion of Phase I portion of Pancreatic Cancer Study - GlobeNewswireMay 10, 2022 | streetinsider.comForm 10-Q XBiotech Inc. For: Mar 31 - StreetInsider.comSee More Headlines Receive XBIT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for XBiotech and its competitors with MarketBeat's FREE daily newsletter. Email Address XBIT Company Calendar Today9/24/2023Next Earnings (Estimated)9/27/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:XBIT CUSIPN/A CIK1626878 Webwww.xbiotech.com Phone(512) 386-2900Fax512-386-5505Employees84Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.19) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-32,900,000.00 Net Margins-820.45% Pretax Margin-1,283.13% Return on Equity-11.95% Return on Assets-11.67% Debt Debt-to-Equity RatioN/A Current Ratio47.08 Quick Ratio47.08 Sales & Book Value Annual Sales$1.98 million Price / Sales67.02 Cash FlowN/A Price / Cash FlowN/A Book Value$7.90 per share Price / Book0.55Miscellaneous Outstanding Shares30,436,000Free Float21,792,000Market Cap$132.70 million OptionableOptionable Beta1.24 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. John Simard (Age 61)Founder, Pres, CEO & Chairman Comp: $4.67MDr. Sushma Shivaswamy Ph.D. (Age 45)Chief Scientific Officer Comp: $381.24kMs. Angela Hu (Age 39)Director of Fin., Principal Financial & Accounting Officer and Financial Controller Key CompetitorsDesign TherapeuticsNASDAQ:DSGNTrevi TherapeuticsNASDAQ:TRVIBioLineRxNASDAQ:BLRXAnnexonNASDAQ:ANNXPuma BiotechnologyNASDAQ:PBYIView All CompetitorsInstitutional OwnershipCitadel Advisors LLCSold 5,600 shares on 8/15/2023Ownership: 0.000%BlackRock Inc.Bought 27,651 shares on 8/11/2023Ownership: 0.952%Geode Capital Management LLCBought 18,098 shares on 8/11/2023Ownership: 0.569%Renaissance Technologies LLCSold 24,160 shares on 8/11/2023Ownership: 0.093%BNP Paribas Arbitrage SNCBought 8,114 shares on 8/9/2023Ownership: 0.031%View All Institutional Transactions XBIT Stock - Frequently Asked Questions How have XBIT shares performed in 2023? XBiotech's stock was trading at $3.51 on January 1st, 2023. Since then, XBIT shares have increased by 24.2% and is now trading at $4.36. View the best growth stocks for 2023 here. When is XBiotech's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, September 27th 2023. View our XBIT earnings forecast. What is John Simard's approval rating as XBiotech's CEO? 20 employees have rated XBiotech Chief Executive Officer John Simard on Glassdoor.com. John Simard has an approval rating of 58% among the company's employees. This puts John Simard in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of XBiotech own? Based on aggregate information from My MarketBeat watchlists, some companies that other XBiotech investors own include Micron Technology (MU), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Walt Disney (DIS), Cisco Systems (CSCO), NVIDIA (NVDA), Inovio Pharmaceuticals (INO), Intel (INTC), Pfizer (PFE) and Block (SQ). When did XBiotech IPO? (XBIT) raised $76 million in an IPO on Wednesday, April 15th 2015. The company issued 4,000,000 shares at a price of $18.00-$20.00 per share. WR Hambrecht + Co served as the underwriter for the IPO. What is XBiotech's stock symbol? XBiotech trades on the NASDAQ under the ticker symbol "XBIT." Who are XBiotech's major shareholders? XBiotech's stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (0.95%), Geode Capital Management LLC (0.57%), EA Series Trust (0.16%), Renaissance Technologies LLC (0.09%), Virtu Financial LLC (0.03%) and BNP Paribas Arbitrage SNC (0.03%). Insiders that own company stock include John Simard, Street Financial SA Bay and W Thorpe Mckenzie. View institutional ownership trends. How do I buy shares of XBiotech? Shares of XBIT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is XBiotech's stock price today? One share of XBIT stock can currently be purchased for approximately $4.36. How much money does XBiotech make? XBiotech (NASDAQ:XBIT) has a market capitalization of $132.70 million and generates $1.98 million in revenue each year. The biopharmaceutical company earns $-32,900,000.00 in net income (profit) each year or ($1.19) on an earnings per share basis. How can I contact XBiotech? XBiotech's mailing address is 5217 Winnebago Ln, AUSTIN TX, 78744. The official website for the company is www.xbiotech.com. The biopharmaceutical company can be reached via phone at (512) 386-2900, via email at swhitehurst@xbiotech.com, or via fax at 512-386-5505. This page (NASDAQ:XBIT) was last updated on 9/24/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding XBiotech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.